GTX initiated with "market outperform"

03/25/08 - Rodman & Renshaw

NEW YORK, March 25 (newratings.com) - Analysts at Rodman & Renshaw initiate coverage of GTX Inc (GTXI) with a "market outperform" rating. The target price is set to $22.

In a research note published this morning, the analysts mention that the company is currently developing Acapodene in a pivotal Phase III clinical trial for the chemoprevention of prostate cancer in high risk male patients. GTX is likely to file a new drug application in the US for Acapodene if statistical parameters are achieved in the Phase III trial, the analysts say. GTX has a strategic collaboration with Merck for the SARM programme and GTX’s Ostarine is the most advanced compound in the SARM arena, Rodman & Renshaw adds.